TITAN PHARMACEUTICALS INC

TTNP

Explore Our Financial Data > Companies > TITAN PHARMACEUTICALS INC
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
TTNP
CIK0000910267
SIC2836
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupBiological Products, Except Diagnostic Substances

Contact

Address400 OYSTER POINT BLVD, SUITE 505, SAN FRANCISCO, CA, 94080
Website titanpharm.com
Phone6502444990
CEODavid E. Lazar
Employees10

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
RevenueN/A
Pre-Tax Income$-2.80 million
Net Income$-2.80 million
Net Income to Common$-2.80 million
EPS$-2.63
View All
Balance Sheet
Cash$2.80 million
Assets$3.05 million
Liabilities$263,000.00
Common Equity$2.79 million
Liabilities & Equity$3.05 million
View All
Cash Flow Statement
Net Income$-2.80 million
Cash From Operating Activities$-2.75 million
Cash From Investing ActivitiesN/A
Cash From Financing Activities$1.46 million
Change in Cash$-1.29 million
View All
Calculations
NOPAT$-1.83 million
EBITDA$-2.80 million
Price to EarningsN/A
Price to Book$2.20
ROE-82.72%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Titan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan Corporation

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (“Titan” or “TTNP”) today announced the successful closing of its previously announced merger with Black Titan Corporation (“Black Titan”) and TalenTec Sdn. Bhd. (“TalenTec”). Following the merger, the combined company's ordinary shares, $0.0001 par value per share, will trade on the Nasdaq stock exchange under the ticker symbol NASDAQ: BTTC. Pursuant to the Merger and Contribution and Share Exchange Agreement dated August 1

Article Link

Titan Pharmaceuticals: Q2 Earnings Snapshot

NEW YORK (AP) — Titan Pharmaceuticals Inc. TTNP) on Thursday reported a loss of $689,000 in its second quarter. On a per-share basis, the New York-based company said it had a loss of 65 cents.

Article Link

Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the “Purchase Agreement”) with Blue Harbour Asset Management L.L.C-FZ (“Blue Harbour”), it has completed a private placement of the Company’s newly designated Series C Convertible Preferred Stock (the “Preferred Stock”). Pursuant to the Purchase Agreement, Blue Harbour purchased 60,000 shares of Preferred Stock for an

Article Link

Titan announces filing of registration statement for proposed combination

Titan Pharmaceuticals (TTNP) announced the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission of a registration statement on Form F-4 in connection with the proposed combination of Titan and TalenTec, which includes Titan’s preliminary proxy statement. As previously announced on August 19, 2024, Titan and TalenTec have entered into a Merger and Contribution and Share Exchange Agreement regarding a business combination, pursuant to which Titan will be combined with

Article Link

Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.

NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission (“SEC”) of a registration statement on Form F-4 in connection with the proposed combination of Titan and TalenTec Sdn. Bhd. (f/k/a KE Sdn. Bhd.) (“TalenTec”), which includes Titan’s preliminary proxy statement (the “Form F-4”) As previously announced on August 19, 2024, Titan and Ta

Article Link